Sex hormone replacement therapy reverses altered venous contractility in rats after pharmacological ovariectomy.

Várbíró S, Vajó Z, Nádasy GL, Monos E, Acs N, Lóránt M, Felicetta JV, Székacs B

Menopause (New York, N.Y.)1 Mar 2002Cited by 9 (Europe PMC)

PMID11875331DOI10.1097/00042192-200203000-00007PepBankPUB-11875331

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats, triptorelin-induced pharmacological ovariectomy reduced body-weight-adjusted saphenous vein diameter versus controls.
In plain wordsIn rats, triptorelin-induced ovarian suppression reduced vein diameter adjusted for body weight compared with controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBody-weight-adjusted venous diameter after ovariectomy
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Non-ovariectomized controls
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
Venous diameter, adjusted for body weight, was significantly decreased after pharmacological ovariectomy.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533101
02AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats with triptorelin-induced pharmacological ovariectomy, hormone replacement increased saphenous vein diameter.
In plain wordsIn rats with triptorelin-induced ovarian suppression, hormone replacement increased vein diameter compared with no replacement.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseVenous diameter with hormone replacement
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Pharmacological ovariectomy without hormone replacement
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
HRT increased the diameter.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533102
03AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats, norepinephrine-induced venous contraction was lower after triptorelin-induced pharmacological ovariectomy than in controls.
In plain wordsIn rats, vein contraction in response to norepinephrine was lower after triptorelin-induced ovarian suppression than in controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseNorepinephrine-induced contraction after ovariectomy
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Non-ovariectomized controls
Outcome group
Vascular function · Cardiovascular
Measurements
Norepinephrine contraction
15.2%
pharmacological ovariectomy
Norepinephrine contraction
19.2%
control
Source sentences
Summary
The presence of sex hormones augmented norepinephrine contraction measured at physiological pressures (control: 19.2 +/- 2.3%; pharmacological ovariectomy: 15.2 +/- 1.4%, p < 0.05 and 17.8 +/- 2.2% following HRT).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533103
04AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats with triptorelin-induced pharmacological ovariectomy, sex hormone replacement augmented norepinephrine-induced venous contraction.
In plain wordsIn rats with triptorelin-induced ovarian suppression, hormone replacement increased vein contraction in response to norepinephrine compared with no replacement.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseNorepinephrine-induced contraction with hormone replacement
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Pharmacological ovariectomy without hormone replacement
Outcome group
Vascular function · Cardiovascular
Measurements
Norepinephrine contraction
17.8%
following HRT
Norepinephrine contraction
15.2%
pharmacological ovariectomy
Source sentences
Summary
The presence of sex hormones augmented norepinephrine contraction measured at physiological pressures (control: 19.2 +/- 2.3%; pharmacological ovariectomy: 15.2 +/- 1.4%, p < 0.05 and 17.8 +/- 2.2% following HRT).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533104
05AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats, myogenic saphenous vein tone did not change after triptorelin-induced pharmacological ovariectomy.
In plain wordsIn rats, spontaneous vein tone did not change after triptorelin-induced ovarian suppression compared with controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMyogenic venous tone after ovariectomy
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Non-ovariectomized controls
Outcome group
Vascular function · Cardiovascular
Measurements
Myogenic tone
6.9%
ovariectomy
Myogenic tone
8%
control
Source sentences
Summary
Myogenic (spontaneous) tone of the saphenous vein did not change after ovariectomy, but it was lowered by hormone replacement (control: 8 +/- 1.1%; ovariectomy: 6.9 +/- 2.5%; ovariectomy + HRT: 2.7 +/- 1.1%, p < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533105
06AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Mechanism
In rats with triptorelin-induced pharmacological ovariectomy, hormone replacement lowered myogenic saphenous vein tone.
In plain wordsIn rats with triptorelin-induced ovarian suppression, hormone replacement lowered spontaneous vein tone compared with no replacement.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMyogenic venous tone with hormone replacement
Study
Sprague-Dawley ratsn = 20
Pharmacological ovariectomy
Comparator
Pharmacological ovariectomy without hormone replacement
Outcome group
Vascular function · Cardiovascular
Measurements
Myogenic tone
2.7%
ovariectomy plus HRT
Myogenic tone
6.9%
ovariectomy
Source sentences
Summary
Myogenic (spontaneous) tone of the saphenous vein did not change after ovariectomy, but it was lowered by hormone replacement (control: 8 +/- 1.1%; ovariectomy: 6.9 +/- 2.5%; ovariectomy + HRT: 2.7 +/- 1.1%, p < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty Sprague-Dawley rats were pharmacologically ovariectomized by triptorelin.
Summary · context
Ten of these rats received combined sex hormone replacement (HRT) with estradiol propionate and medroxyprogesterone acetate.
Summary · context
Ten animals without ovariectomy served as controls.
Summary · context
After 3 months of treatment, segments of the saphenous vein were dissected.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1187533106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.